TMO

Thermo Fisher Scientific Inc

Add to Watchlist

Advanced Chart

460.720

+5.98(1.315%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

461.720

Open

453.490

VWAP

459.08

Vol

1.69M

Mkt Cap

173.97B

Low

451.435

Amount

775.81M

EV/EBITDA(TTM)

18.70

Total Shares

381.72M

200.65B

EV/OCF(TTM)

26.48

P/S(TTM)

4.01

Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, the Company provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, the Company provides an offering of instruments and the supporting consumables, software and services that are used for a range of applications. The Company’s Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

10.85B

+4.68%

5.585

+8.45%

11.77B

+3.33%

6.525

+6.96%

10.90B

+2.88%

5.504

+4.24%

Estimates Revision

The market is revising Upward the revenue expectations for Thermo Fisher Scientific Inc. (TMO) for FY2025, with the revenue forecasts being adjusted by 0.45% over the past three months. During the same period, the stock price has changed by 12.16%.

Revenue Estimates for FY2025

Revise Upward

+0.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.23%

In Past 3 Month

Stock Price

Go Up

+12.16%

In Past 3 Month

19 Analyst Rating

18.43% Upside

Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 545.61 USD with a low forecast of 450.00 USD and a high forecast of 620.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

17 Buy

2 Hold

0 Sell

Strong Buy

18.43% Upside

Current: 460.720

Low

450.00

Averages

545.61

High

620.00

18.43% Upside

Current: 460.720

Low

450.00

Averages

545.61

High

620.00

Barclays

Equal Weight

maintain

$450 -> $495

2025-07-24

Reason

Barclays

Price Target

$450 -> $495

2025-07-24

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Thermo Fisher to $495 from $450 and keeps an Equal Weight rating on the shares. The company reported a Q2 beat, the analyst tells investors in a research note.

Wells Fargo

Brandon Couillard

Overweight

maintain

$570 -> $565

2025-07-24

Reason

Wells Fargo

Brandon Couillard

Price Target

$570 -> $565

2025-07-24

maintain

Overweight

Reason

Wells Fargo analyst Brandon Couillard lowered the firm's price target on Thermo Fisher to $565 from $570 and keeps an Overweight rating on the shares. Aside from a solid Q2 beat/raise, the firm is encouraged that Thermo Fisher addressed the elephant in the room by pointing to realistic +3%-6% core growth expectations in 2026/2027 and an updated LRP, but with higher margin exp goals.

Baird

Outperform

maintain

$553 -> $567

2025-07-24

Reason

Baird

Price Target

$553 -> $567

2025-07-24

maintain

Outperform

Reason

Baird raised the firm's price target on Thermo Fisher to $567 from $553 and keeps an Outperform rating on the shares. The firm updated its guidance following Q2 results and said its outlook helps the LRP overhang.

BofA

Buy

maintain

$545 -> $560

2025-07-24

Reason

BofA

Price Target

$545 -> $560

2025-07-24

maintain

Buy

Reason

BofA raised the firm's price target on Thermo Fisher to $560 from $545 and keeps a Buy rating on the shares after the company reported a "strong" Q2 and updated its FY25 guidance. The "big news" was that Thermo Fisher "semi-surprisingly" provided an long-range plan update, which was very well-received and relieved a "major overhang," says the analyst, who thinks the company "threaded the needle on new LRP messaging."

HSBC

Sidharth Sahoo

Buy

Hold

downgrade

$510

2025-07-24

Reason

HSBC

Sidharth Sahoo

Price Target

$510

2025-07-24

downgrade

Buy

Hold

Reason

HSBC analyst Sidharth Sahoo downgraded Thermo Fisher to Hold from Buy with a $510 price target.

UBS

Dan Leonard

Neutral

maintain

$460 -> $500

2025-07-24

Reason

UBS

Dan Leonard

Price Target

$460 -> $500

2025-07-24

maintain

Neutral

Reason

UBS analyst Dan Leonard raised the firm's price target on Thermo Fisher to $500 from $460 and keeps a Neutral rating on the shares. Thermo Fisher reported a Q2 beat with "responsible" forward framing, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Thermo Fisher Scientific Inc (TMO.N) is 19.37, compared to its 5-year average forward P/E of 24.14. For a more detailed relative valuation and DCF analysis to assess Thermo Fisher Scientific Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

24.14

Current PE

19.37

Overvalued PE

27.00

Undervalued PE

21.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

20.66

Current EV/EBITDA

17.49

Overvalued EV/EBITDA

22.76

Undervalued EV/EBITDA

18.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

5.02

Current PS

3.78

Overvalued PS

5.62

Undervalued PS

4.41

Financials

Annual

Quarterly

FY2025Q2

YoY :

+2.98%

10.86B

Total Revenue

FY2025Q2

YoY :

-2.59%

1.92B

Operating Profit

FY2025Q2

YoY :

-1.22%

1.62B

Net Income after Tax

FY2025Q2

YoY :

+5.94%

4.28

EPS - Diluted

FY2025Q2

YoY :

-33.43%

1.11B

Free Cash Flow

FY2025Q2

YoY :

-1.50%

40.62

Gross Profit Margin - %

FY2025Q2

YoY :

-24.08%

14.28

FCF Margin - %

FY2025Q2

YoY :

+1.15%

14.91

Net Margin - %

FY2025Q2

YoY :

-0.64%

9.34

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 4146.94% over the last month.

Sold

0-3

Months

8.3M

USD

3-6

Months

10.6M

USD

6-9

Months

11.8M

USD

0-12

Months

54.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

2.1K

USD

Months

0-12

8.9K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.3M

Volume

6-9

Months

798.3K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.5M

Volume

Months

6-9

1.6M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

277.5K

USD

6-9

Months

8.0K

USD

0-12

Months

8.0K

USD

Bought

0-3

0.0

USD

Months

3-6

121.5K

USD

Months

6-9

0.0

USD

Months

0-12

16.0K

USD

Months

Insider

Insiders areSelling! The selling amount has increased 4146.94% over the last month.

Sold

0-3

Months

8.3M

USD

3-6

Months

10.6M

USD

6-9

Months

11.8M

USD

0-12

Months

54.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

2.1K

USD

Months

0-12

8.9K

USD

Months

TMO News & Events

Events Timeline

2025-08-07 (ET)

2025-08-07

08:13:17

Trinity Biotech announces launch of FDA-cleared preeclampsia testing service

2025-07-23 (ET)

2025-07-23

09:55:01

Early notable gainers among liquid option names on July 23rd

2025-07-23

09:10:04

Thermo Fisher CFO Stephen Williamson to retire, Jim Meyer to succeed

News

3.0

15:00 PMNASDAQ.COM

VONV, BLK, TMO, PGR: Large Inflows Detected at ETF

3.0

08-07NASDAQ.COM

IYH's Holdings Imply 20% Gain Potential

5.0

08-04Yahoo Finance

Contract Manufacturing Market Forecast to 2030, with Case Studies of Thermo Fisher Scientific and Flextronics

People Also Watch

Taiwan Semiconductor Manufacturing Co Ltd

Berkshire Hathaway Inc

FAQ

What is Thermo Fisher Scientific Inc (TMO) stock price today?

The current price of TMO is 460.72 USD — it has increased 1.32 % in the last trading day.

TMO

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

TMO News & Events

Events Timeline

News

People Also Watch

FAQ

What is Thermo Fisher Scientific Inc (TMO) stock price today?

What is Thermo Fisher Scientific Inc (TMO)'s business?

What is the price predicton of TMO Stock?

What is Thermo Fisher Scientific Inc (TMO)'s revenue for the last quarter?

What is Thermo Fisher Scientific Inc (TMO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Thermo Fisher Scientific Inc (TMO)'s fundamentals?

How many employees does Thermo Fisher Scientific Inc (TMO). have?

What is Thermo Fisher Scientific Inc (TMO) market cap?